Gynecologic Oncology | Specialty

Preoperative Imaging Remains Integral to Endometrial Cancer Diagnosis

January 15th 2018

Ingfrid Haldorsen, MD, discusses the role of imaging in the diagnosis of patients with endometrial cancer.

Global HPV Vaccination Reshaping Standard of Care for Cervical Cancer Prevention

January 15th 2018

Xavier Bosch, MD, discusses a second-generation vaccination against HPV for the prevention of cervical cancer.

Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer

January 13th 2018

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

Dr. Haldorsen on the Importance of Imaging in the Diagnosis of Endometrial Cancer

January 11th 2018

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the importance of imaging in the diagnosis of endometrial cancer.

Expert Highlights Genetic Testing, Immunotherapy in Endometrial Cancer

January 11th 2018

Martee L. Hensley, MD, discusses the role of MSI-H and dMMR testing in the management of endometrial cancer.

Dr. Taylor on Treatments in Development for Endometrial Cancer

January 4th 2018

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

Dr. Mahantsetty on Unmet Needs in Cervical Cancer

December 29th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, India, discusses unmet needs for patients with cervical cancer.

Dr. Hensley on Lynch Syndrome in Endometrial Cancer

December 28th 2017

Martee L. Hensley, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses Lynch syndrome for patients with endometrial cancer.

Dr. Ledermann on Systemic Treatment for Rare Gynecologic Tumors

December 27th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Dr. Taylor on the Current Treatment Landscape for Endometrial Cancer

December 21st 2017

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the current treatment landscape of advanced endometrial cancer.

Cotesting Unlikely to Detect More Cervical Cancers Than HPV Testing Alone

December 20th 2017

Use of both a Pap smear and an HPV test did not identify more cervical cancers than HPV testing alone.

HPV 16/18 Linked to Increased Relapse Risk in Cervical Cancer

December 19th 2017

Persistent HPV 16/18 infection correlated with higher locoregional relapse, overall relapse, and was also associated with early relapses in women with locally advanced cervical cancers treated with radical radiochemotherapy.

Dr. Mahantshetty Discusses Chemoradiation in Cervical Cancer

December 16th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses chemoradiation in patients with cervical cancer.

Study Finds Significant Survival Disparities in HPV-related Cancer

December 9th 2017

Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities

Dr. Haldorsen Discusses the Challenges With Imaging in Endometrial Cancer

November 28th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the challenges with imaging in endometrial cancer.

Promise on the Horizon in Advanced Endometrial Cancer

November 21st 2017

Alexandra Taylor, MD, discusses the advances with targeted therapies in endometrial cancer, as well as the challenges that still exist in the treatment and management of patients with advanced disease.

Involved Margins, High-Risk HPV Post-Treatment Predict Treatment Failure in Cervical Cancer

November 14th 2017

Results from a systemic review and meta-analysis of data collected from nearly 45,000 women treated for cervical precancer found that high-risk HPV posttreatment was a more accurate predictor of treatment failure than incomplete rescission.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017